{
    "Clinical Trial ID": "NCT00562718",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Surgery and Chemotherapy",
        "  Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.",
        "  capecitabine",
        "  adjuvant therapy",
        "radiation therapy"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically or cytologically confirmed invasive adenocarcinoma of the breast, meeting 1 of the following high-risk criteria:",
        "  T3 or T4 primary tumor",
        "  4 or more involved axillary lymph nodes (N2 nodal stage)",
        "  Completed surgical excision",
        "  No immediate reconstruction with autologous flap reconstruction",
        "  Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion",
        "  No residual breast cancer",
        "  Microscopically positive margins are allowed if a re-excision is not felt to be clinically justified",
        "  Candidate for radiotherapy",
        "  Must not require bilateral radiotherapy",
        "  No metastatic (stage IV) breast cancer by AJCC staging criteria",
        "  Hormone receptor status not specified",
        "  No CNS disorders",
        "  PATIENT CHARACTERISTICS:",
        "  Life expectancy  6 months",
        "  Karnofsky performance status 70-100%",
        "  Menopausal status not specified",
        "  Ambulatory",
        "  Hemoglobin > 9 g/dL",
        "  Platelet count > 100,000/mm\u00b3",
        "  ANC > 1,500/mm\u00b3",
        "  Serum AST, ALT, and alkaline phosphatase  2 times upper limit of normal (ULN)",
        "  Total bilirubin normal",
        "  Creatinine clearance > 50 mL/min",
        "  Negative pregnancy test",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception during study and for 30 days after the last study drug administration",
        "  No serious, uncontrolled, concurrent infection(s)",
        "  No diabetes with current or history of delayed wound healing or skin ulcers",
        "  No autoimmune connective tissue disorder",
        "  No prior unanticipated severe reaction to fluoropyrimidine therapy, known sensitivity to 5-fluorouracil, or known dihydropyrimidine dehydrogenase (DPD) deficiency",
        "  No other carcinomas within the last five years except cured non-melanoma skin cancer and in-situ cervical cancer",
        "  No clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months",
        "  No other serious uncontrolled medical conditions that the investigator feels might compromise study participation, including any of the following:",
        "  Uncontrolled seizures",
        "  Psychiatric disability judged by the investigator to be clinically significant",
        "  Physically intact upper gastrointestinal tract",
        "  No malabsorption syndrome",
        "  No uncompensated coagulopathy",
        "  No patients whose breast size or body contour puts them at increased risk for skin desquamation from standard radiotherapy",
        "  Able to read and speak English",
        "  PRIOR CONCURRENT THERAPY:",
        "  Fully recovered from surgery and chemotherapy with completely healed surgical wounds",
        "  At least 4 weeks since completion of prior chemotherapy regimen, excluding trastuzumab (Herceptin\u00ae)",
        "  Concurrent trastuzumab allowed at the physician's discretion",
        "  More than 4 weeks since prior participation in any investigational drug study",
        "  At least 4 weeks since prior and no concurrent sorivudine or brivudine",
        "  More than 2 weeks since prior major surgery",
        "  No prior capecitabine",
        "  No prior radiotherapy to the chest or ipsilateral lymphatics",
        "  No concurrent hormonal therapy during course of chemotherapy or radiation therapy",
        "  No concurrent allopurinol or cimetidine",
        "  Concurrent coumadin is allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Safety",
        "  Primarily Grade 1 and 2 toxicities attributable to capecitabine",
        "Time frame: 1 year",
        "Results 1: ",
        "  Arm/Group Title: Surgery and Chemotherapy",
        "  Arm/Group Description: Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.",
        "  capecitabine",
        "  adjuvant therapy",
        "  radiation therapy",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  12.6"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/39 (15.38%)",
        "  Radiation Dermatitis  6/39 (15.38%)"
    ]
}